Skip to content

Splinting to Treat Hand Osteoarthritis

Splinting to Treat Interphalangeal Joint Deformity in Hand Osteoarthritis(Splint OA Study)

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01249391
Acronym
SPLINTOA
Enrollment
45
Registered
2010-11-29
Start date
2010-09-30
Completion date
2011-12-31
Last updated
2016-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hand Osteoarthritis

Keywords

Hand, osteoarthritis, splint, pain, deformity, function

Brief summary

Osteoarthritis (OA) is the most common form of arthritis and the hand is the most frequently affected site.Interphalangeal (IP) joints (the small joints of the fingers) are often involved causing pain, progressive loss of hand function and deformity. Deviation, or bending to the side, of IP joints (IPJs) with significant functional and cosmetic consequences for the individual is common. There are no drugs which can slow the disease process so there is reliance on symptomatic treatment such as pain relief and hand therapy. Joint thermoplastic splinting (moulded plastic splints that are custom-made) is employed by hand therapists in other settings, but to the investigators knowledge no studies have formally investigated the effect of splinting in IP OA. By resting inflamed tissues and correcting joint alignment, a beneficial role for splinting in IP OA is likely. In this study, the investigators want to test whether thermoplastic splinting of deviated IP joints due to OA will 1) improve joint alignment 2) ameliorate soft tissue inflammation, and whether as a consequence 3) pain and overall hand function will be improved. Adults with hand OA with 'affected' IP joints (symptoms from OA associated with deviation of the joint on X-ray)will be recruited from a specialist hand osteoarthritis clinic. Initially this will be for distal IP (DIP) joints. In the intervention group (30 patients), an 'intervention' joint for splinting will be identified as the most painful deviated DIP joint in the past week leading up to enrolment. Up to 3 other 'affected' DIP joints on either hand will not be splinted but will be monitored as 'control' joints. In the control group (15 patients), an affected joint will be monitored but not splinted. Assessment of joint pain, hand function by a hand therapist, deformity (by X-ray)and joint inflammation will take place at baseline, during and at the end of splinting period of 3 months, and also at 6 months,to assess whether any changes are persistent. In this way, the efficacy of splinting of IP joints in OA will be assessed.

Interventions

DEVICESplinting

Gutter thermoplastic custom-made splint for nominated joint, to be worn at night-time for consecutive nights for 3 months

Sponsors

National Institute for Health Research, United Kingdom
CollaboratorOTHER_GOV
Imperial College London
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Aged 18 - 90 * Definite diagnosis of IPJ osteoarthritis (American College of Rheumatology criteria for OA) * A previous radiograph of the hands with changes consistent with OA * Either, Intervention group: At least 2 'affected' IPJs (symptomatic (\>2/10 average pain on 0-10 scale in past week) and radiological OA associated with 10 degrees of either radial or ulnar deviation of the joint evident clinically and on Xray) * OR Control group: At least 1 'affected' IPJ (symptomatic (\>2/10 average pain on 0-10 scale in past week) and radiological OA associated with 10 degrees of either radial or ulnar deviation of the joint evident clinically and on X-ray) * Stable oral therapy for month prior to study entry e.g. non steroidal anti-inflammatory drugs (NSAIDs) * Capable of providing written informed consent

Exclusion criteria

* Contraindication to splinting e.g. allergy to materials * Planned surgery during study period * Oral, intramuscular or intraarticular steroids within 3 months of study entry * Intraarticular hyaluronans to any nominated IP joints within 6 months of study entry * Not resident in UK * Pregnancy * Other inflammatory arthritis * History of psoriasis * Participation in other intervention trials * Patients with any uncontrolled or severe medical problems which in the opinion of the investigator makes them unsuitable for study participation * Unable to give informed written consent in English

Design outcomes

Primary

MeasureTime frameDescription
Pain in nominated joint3 monthsAssessed via numerical rating scale

Secondary

MeasureTime frameDescription
Radiological deviation of nominated joint3 monthsDegrees of radial or ulnar deviation of joint will be assessed radiographically.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026